Thymosin-α1 for Recurrent Implantation Failure
ConditionRecurrent Implantation Faliure
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age18-40
SponsorFakih IVF Fertility Center
About this trial
Clinical trial evaluating the safety and efficacy of Thymosin-α1 (Tα1) as an adjunctive immunomodulatory therapy in women with unexplained recurrent implantation failure (RIF) undergoing IVF/ICSI cycles.
Eligibility criteria
Qualifiers
-Women 18-40 years
-RIF- ≥2 failed embryo transfers with PGT-a tested euploid embryos
- Normal parental karyotypes
- Normal uterine cavity on imaging
Disqualifiers
Identified/correctable non-immune cause of RPL (chromosomal, anatomic, endocrine)
- Active malignancy
-Active infection
- Uncontrolled systemic disease
Trial design
Treatments tested in this trial
- Thymosin Alpha1
- Placebo Control
Treatment groups
136 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov